Dual Aptamers‐Based SETDB1 PROTACs as Effective Anti‐Tumor Strategies for Breast Cancer
Advanced Science · 2026
DOI: 10.1002/advs.202521159 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Yanxuan Guo und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Province and Ministry Co-Sponsored Collaborative Innovation Center for Medical Epigenetics, State Key Laboratory of Experimental Hematology, Key …. Hauptthemen laut MEDLINE: Breast Neoplasms, Aptamers, Nucleotide, Histone-Lysine N-Methyltransferase, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Tianjin Municipality.
Abstract (Originalsprache)
PROteolysis TArgeting Chimeras (PROTACs) have emerged as a promising strategy for drug development targeting oncogenic proteins. Here, we report the development and characterization of dual aptamer‐based PROTACs targeting SET domain bifurcated histone lysine methyltransferase 1 (SETDB1), a key epigenetic regulator implicated in breast cancer progression, drug resistance, and tumor immune evasion. Using the Systematic Evolution of Ligands by Exponential Enrichment (SELEX) process, we identified a high‐affinity single‐stranded DNA (ssDNA) aptamer against SETDB1. This aptamer was conjugated to the nucleolin‐targeting aptamer AS1411, generating a single‐strand PROTAC (AP‐SETDB1‐S6A) and a partial double‐strand PROTAC (AP‐SETDB1‐D2), both of which exhibit good serum stability. These two PROTACs directly penetrate breast cancer cells and effectively recruit the E3 ligase mouse double minute 2 homolog (MDM2) to SETDB1, inducing proteasome‐dependent degradation of SETDB1. Functional assays demonstrated that both AP‐SETDB1‐S6A and AP‐SETDB1‐D2 significantly inhibit breast cancer cell proliferation and migration, and resensitize drug‐resistant breast cancer cells to tamoxifen. Notably, they further enhance the cytotoxic activity of CD8 + T cells against breast cancer cells and directly target breast cancer cells to suppress tumor growth in vivo. This study establishes dual aptamers‐based PROTACs targeting SETDB1, offering effective therapeutic strategies for breast cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Province and Ministry Co-Sponsored Collaborative Innovation Center for Medical Epigenetics, State Key Laboratory of Experimental Hematology, Key Laboratory of Breast Cancer Prevention and Therapy (Tianjin Medical Un…
- Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
ORCID-Profile: Chenghao Xuan
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Tianjin Municipality
Zitieren
APA
Guo, Y., Lv, Y., Huang, S., Liu, C., Ouyang, Y., Lan, B., & Xuan, C. (2026). Dual Aptamers‐Based SETDB1 PROTACs as Effective Anti‐Tumor Strategies for Breast Cancer. Advanced Science. https://doi.org/10.1002/advs.202521159
Vancouver
Guo Y, Lv Y, Huang S, Liu C, Ouyang Y, Lan B, et al. Dual Aptamers‐Based SETDB1 PROTACs as Effective Anti‐Tumor Strategies for Breast Cancer. Advanced Science. 2026. doi:10.1002/advs.202521159
BibTeX
@article{Guo2026,
author = {Guo, Yanxuan and Lv, Yingge and Huang, Shuyu and Liu, Chang and Ouyang, Yan and Lan, Bei and Xuan, Chenghao},
title = {Dual Aptamers‐Based SETDB1 PROTACs as Effective Anti‐Tumor Strategies for Breast Cancer},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202521159}
}
EUVIMED